Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Sprimont – page 72

1 231 clinical trials in Sprimont, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sprimont at a glance
1 231
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 231 trials in Sprimont

Open in trial search

Pulmonary fibrosis

Not recruiting

Study of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Endometrial cancer

Not recruiting

Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Study on BI 1839100 for Reducing Cough in Patients with Idiopathic or Progressive Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 1839100
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Safety and Efficacy of RO7204239 and Risdiplam for Patients with Spinal Muscular Atrophy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Sponsor:F. Hoffmann-La Roche AG

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Sparsentan and Dapagliflozin for Patients with Immunoglobulin A Nephropathy (IgAN)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Travere Therapeutics Inc.

Study on the Effects of Inhaled Treprostinil for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GAD20-209-FSP-A1
  • Sponsor:Nouscom S.r.l.

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Genmab A/S

Study on BI 1819479 to Improve Lung Function in Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 1819479
  • Sponsor:Boehringer Ingelheim Espana S.A.

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Unicancer

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Sprimont

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on optimizing treatment strategies for patients with functional dyspepsia and related gastrointestinal conditions. The research explores alternative approaches to managing chronic proton pump inhibitor usage.

  • Medication De-prescribing Strategies
  • Digestive System Disorders
  • Treatment Optimization

This primary care investigation evaluates different therapeutic approaches, including on-demand medication use and alternative treatments, to improve patient outcomes while reducing long-term medication dependency.

02 Primary Care Innovation

Ground-breaking research examining the effectiveness of various approaches to managing reflux and heartburn symptoms in primary care settings. The study aims to establish more patient-centered treatment protocols.

  • Patient-Centered Care
  • Symptom Management
  • Treatment Alternatives

The research compares traditional medication reduction methods with innovative approaches, including the use of alginate-based alternatives.

03 Therapeutic Management

Clinical investigation focused on developing evidence-based deprescribing protocols for long-term medication users. The research evaluates multiple therapeutic strategies to identify optimal treatment pathways.

  • Clinical Effectiveness
  • Treatment Optimization
  • Patient Safety

This comparative study aims to establish the most effective and patient-friendly approach to reducing unnecessary long-term medication use while maintaining symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.